MedVasc AB has successfully completed production and testing activities in accordance with its previously communicated plan. In parallel, the company closed a new financing round at the end of 2025, raising SEK 24 million through subscriptions exclusively from existing shareholders.
The strong participation from current owners demonstrates continued confidence in MedVasc’s strategy, execution capability, and long-term value creation. The board and management view this support as a clear validation of the company’s direction and its ongoing development efforts. With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio™ for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026.
For more information, please contact:
Cathrin Johansson, CEO, MedVasc AB
